Yuhan files an Esopid patent to counter its competitors in the PPI + antacid market

Yuhan Corp. filed the patent for Esopid Tab. (esomeprazole magnesium trihydrate / calcium carbonate), a treatment for gastroesophageal reflux disease (GERD), to block the entry of laggards and competitors of proton pump inhibitors (PPIs) and combination antacid therapy.

Industry sources said Wednesday that Yuhan had obtained a patent on Esopid Tab. 20 / 600㎎ and Esopid Tab. 40 / 600㎎ and registered it Tuesday on the list of patented drugs of the Ministry of Food and Pharmaceutical Safety.

The titular patients are Yuhan and Addpharma, and the patent expires September 4, 2040.

The patent is entitled “A pharmaceutical composition in tablet form comprising omeprazole, esomeprazole or a pharmaceutically acceptable salt thereof and a process for their preparation”.

Yuhan said that the patent on the composition of the tablet could avoid the coating process of the granules or lozenges during manufacturing and make the production process simple.

It can be easily applied at the manufacturing site, and the drug‘s rapid disintegration allows for rapid absorption of the drug, the company said.

In addition, the calcium carbonate included in the drug exhibits high antacid power (acid neutralizing power) which can induce a rapid increase in pH and minimize the use of calcium carbonate to reduce the size of the tablet, a added the company.

Yuhan released Esopid Tab., The combined PPI + antacid drug, in May.

Yuhan co-developed the treatment for GERD with GC Pharma and Kyungdong Pharm, and the three companies respectively obtained the marketing license on the same day in February.

The drug from GC Pharma is called Esoca Tab. and Esocarbo Tab from Kyungdong.

All three products are made at Yuhan Factory in Ochang, North Chungcheong Province.

The local PPI + antacid market started growing in 2018 when Chong Kun Dang launched Eso Duo Tab. (esomeprazole magnesium trihydrate).

In October, Hanmi got approval for Esomezol Plus, which added magnesium hydroxide to Esomesol, a drug gradually changed to treat GERD. This was to heat up the competition in the PPI + antacid combo market.

Korean drugmakers seek uniqueness of PPI + antacid drugs to compete with AstraZeneca’s Nexium Tab. (esomeprazole magnesium).

Outpatient prescriptions of Eso Duo Tab from Chong Kun Dang. recorded 13.9 billion won ($ 11.7 million) last year, showing the growth potential of the combination treatment market.

“In the fiercely competitive PUP market, every drug maker is trying to offer various treatment options using segmented product portfolios,” said an industry official.

Source link

About Margie Peters

Check Also

iPad Pro 2022 – first rumors and what we want to see

We expect there will be a 2022 iPad Pro, given that Apple has revised its …